secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0001818382-23-000104
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte completes enrollment in Phase 2/3 vascular trauma trial; BLA filing planned for Q4 2023
--------------------------------------------------------------------------------

- Enrollment completed in V005 trial; 68 patients received HAV, 51 in primary efficacy analysis for extremity trauma.
- Top-line results expected in Q3 2023; BLA submission to FDA planned for Q4 2023.
- RMAT designation from FDA received in May 2023 increases chance of priority review.
- Ukraine humanitarian program treated 19 trauma patients; data will be included in BLA.
- HAV has >1,000 patient-years of experience across multiple indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000104/0001818382-23-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000104/huma-20230726.htm
  HTML page:      https://secwatch.observer/filing/0001818382-23-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer